Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

June 5, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • INDIA’S CALL FOR PFIZER AGAINST COVID 19

Camouflage: an invisibility cloak?

Food Inhibiting Enzyme That Causes COVID Replication

INDIA’S CALL FOR PFIZER AGAINST COVID 19
  • BiotechToday
  • India

INDIA’S CALL FOR PFIZER AGAINST COVID 19

bioxone December 8, 2020December 8, 2020

SHRESTHA DUTTA, AMITY UNIVERSITY KOLKATA

The authorization for Pfizer’s vaccine candidate came in just 10 months since it initiated developing it, which is the fastest in the history of vaccines.

Pfizer has become the main organization to seek emergency use endorsement of its immunization applicant in India after getting clearance in the UK and Bahrain. Pfizer Inc and BioNTech SE vaccine candidate, BNT162b2, has demonstrated 95 percent viability against Covid during a preparatory clinical trial data examination. It has been approved by the Drugs Controller General of India for emergency use authorization. The advancement is significant since Prime Minister Narendra Modi, during an all-party meet on Friday, referred to specialists to state that India could have the first Covid immunization in weeks and that eight vaccines will be fabricated in India.

An official source reported to a news organization that Pfizer India has presented an application on December 4 to the DCGI looking for emergency use authorization (EUA) for its COVID-19 antibody in India and has sought consent to import the immunization available to be purchased and distributed. It additionally looked for the waiver of clinical preliminaries on the Indian population according to the special arrangements under the New Drugs and Clinical Trials Rules, 2019, to get moment endorsement for emergency use as announced. AIIMS Delhi Director Dr. Randeep Guleria had before said that India was in talks with Pfizer-BioNTech in regards to its COVID-19 antibody candidate. He additionally added that no such correspondence had been started with Moderna for its trial COVID-19 immunization.

Also read: Camouflage: an invisibility cloak?

SOURCE: Pfizer seeks approval for emergency use in India after nod in UK, Bahrain (businesstoday.in)

  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged Covid antibodies Covid-19 vaccine Pfizer approval Pfizer approved in uk pfizer biontech Pfizer biontech vaccine Pfizer covid vaccine Pfizer vaccine update

One thought on “INDIA’S CALL FOR PFIZER AGAINST COVID 19”

  1. Pingback: Food Inhibiting Enzyme That Causes COVID Replication - BioXone

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • World

Food Inhibiting Enzyme That Causes COVID Replication

bioxone December 8, 2020

Thota Kanishka Rao, Amity University Kolkata Chemical compounds in some food or beverages, like green tea, muscadine grapes, and dark chocolate have been known to bind to and block the function of a protease, in the SARS-CoV-2 virus, according to researchers. Proteases are essential to the health and viability of cells and viruses. On the […]

Food

Related Post

  • BiotechToday
  • World

A special protein in rice to protect it against viral infection

BioTech Today July 18, 2021July 18, 2021

Srabani Roy Chowdhury (MAKAUT, WB) Plants possess many mechanisms to safeguard themselves from different pathogenic infections. There is a two-tiered system deployed by plants, as their defense response. They are- Pathogen-Associated Molecular Pattern (PAMP) triggered immunity (also called PTI). It is considered to be a weak immune response, brought into action by plasma membrane-localized pattern […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

O-glycosylation on SARS-CoV-2: Emergence of Model D

BioTech Today July 28, 2021July 27, 2021

Saptaparna Dasgupta, Bennett University SARS-CoV-2, a strain from the Coronavirus family, is responsible for the ongoing global pandemic of COVID-19, taking the lives of millions of people via an infectious respiratory illness. Several studies have been conducted on this virus to find target proteins responsible for the infection as a therapeutic. Thus, spike (S) protein […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

CGRP: A special peptide and its role in Migraine Attacks

BioTech Today August 4, 2021August 4, 2021

Sayak Banerjee, Amity University Kolkata Migraine and its chronification: Migraine is a significant primary headache disorder as it ranks the sixth most prevailing disease and the second cause of disability worldwide. This widespread neurological disease is distinguished by headaches which might take place with or without aura. An aura is a kind of sensory disturbance […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy